Lixisenatide (2 brand names, 1 dosage form, 1 route)
Available dosage forms: SOLUTION.
Routes of administration: SUBCUTANEOUS.
Brand Names
- ADLYXIN
- SOLIQUA 100/33
Indications and Usage
SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Contraindications
SOLIQUA 100/33 is contraindicated: During episodes of hypoglycemia [see Warnings and Precautions (5.6)]. In patients with serious hypersensitivity to insulin glargine, lixisenatide, or any of the excipients in SOLIQUA 100/33. Hypersensitivity reactions including anaphylaxis have occurred with both lixisenatide and insulin glargine [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
Adverse Reactions
The following adverse reactions are discussed elsewhere: Anaphylaxis and Serious Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Acute Pancreatitis [see Warnings and Precautions (5.2)] Hypoglycemia [see Warnings and Precautions (5.6)] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions (5.7)] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.8)] Hypokalemia [see Warnings and Precautions (5.10)] Acute Gallbladder Disease [see Warnings and Precautions (5.12)] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions (5.13)]